What RSU-related activity did Brady Kelly report for Seres Therapeutics (MCRB)?

Brady Kelly reported the vesting and settlement of 181 Restricted Stock Units, converting into 181 shares of Seres Therapeutics (MCRB) Common Stock. These RSUs vest in quarterly installments following initial 25% vesting on specified February dates.

Seres COO sells 64 shares after RSU vesting at $4.55

Q: What insider transactions did MCRB executive Brady Kelly report in this Form 4?

Brady Kelly reported 181 shares of Seres Therapeutics (MCRB) Common Stock acquired via RSU vesting and 64 shares sold at $4.55 per share, reflecting routine equity compensation activity and a subsequent stock sale.

Q: How many Seres Therapeutics (MCRB) shares did Brady Kelly sell and at what price?

Brady Kelly sold 64 shares of Seres Therapeutics (MCRB) Common Stock at $4.55 per share. The transaction occurred on August 17, 2026 and was reported as a sale in the open market or a private transaction.

Q: Was Brady Kelly’s Seres Therapeutics (MCRB) stock sale under a Rule 10b5-1 plan?

Yes. The filing states the 64-share sale was effected under a Rule 10b5-1 plan adopted November 26, 2025, with the intent to cover taxes arising from the vesting of restricted stock units.

Q: What role does Brady Kelly hold at Seres Therapeutics (MCRB)?

Brady Kelly is reported as an EVP, Chief Operating Officer of Seres Therapeutics (MCRB). The transactions disclosed relate to equity compensation (RSUs) and a subsequent sale of shares associated with that role.

Q: How do the reported RSUs for MCRB vest over time for Brady Kelly?

The RSUs vest 25% on an initial February 15 date, with the remainder vesting and settling in 12 equal quarterly installments thereafter. The filing notes that the restricted stock units have no expiration date.

Seres Therapeutics, Inc. (MCRB) executive Brady Kelly, EVP and Chief Operating Officer, reported equity transactions involving company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Seres Therapeutics, Inc. (MCRB) executive Brady Kelly, EVP and Chief Operating Officer, reported equity transactions involving company stock. On August 15, 2026, a total of 181 shares of Common Stock were acquired upon the vesting and settlement of 181 Restricted Stock Units, each RSU representing one share of common stock. On August 17, 2026, Kelly then sold 64 shares of Common Stock at $4.55 per share. According to the disclosure, the sale was effected under a Rule 10b5-1 trading plan adopted on November 26, 2025, with the stated intent to cover taxes related to the RSU vesting.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Brady Kelly

Role See Remarks

Sold 64 shs ($291.20)

Approx. gross sale proceeds $291.20

Type	Security	Shares	Price	Value
Sale	Common Stock ^F2	64	$4.55	$291.20
Exercise	Restricted Stock Units ^{F1, F3}	90	$0.00	$0.00
Exercise	Restricted Stock Units ^{F1, F4}	91	$0.00	$0.00
Exercise	Common Stock ^F1	181	--	--

Holdings After Transaction: Restricted Stock Units — 727 contracts (Direct); Common Stock — 8,679 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Key Figures

Shares sold: 64 shares Sale price: $4.55 per share RSUs converted: 181 Restricted Stock Units +3 more

6 metrics

Shares sold 64 shares Common Stock sale on August 17, 2026

Sale price $4.55 per share Price for 64 Common Stock shares sold on August 17, 2026

RSUs converted 181 Restricted Stock Units RSUs exercised/settled into 181 Common Stock shares on August 15, 2026

Underlying shares from RSUs 181 shares of Common Stock Underlying shares corresponding to vested RSUs reported on August 15, 2026

Net buy/sell shares 64 shares net-sell Net of reported buy/sell activity in this Form 4

10b5-1 plan adoption date November 26, 2025 Adoption date of Rule 10b5-1 plan used for the 64-share sale

Key Terms

Restricted Stock Units, Rule 10b5-1 plan, vest and settle, quarterly installments

4 terms

Restricted Stock Units financial

"The restricted stock units vested and settled as to 25% of the restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

vest and settle financial

"The restricted stock units vested and settled as to 25% of the restricted stock units"

quarterly installments financial

"The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MCRB executive Brady Kelly report in this Form 4?

Brady Kelly reported 181 shares of Seres Therapeutics (MCRB) Common Stock acquired via RSU vesting and 64 shares sold at $4.55 per share, reflecting routine equity compensation activity and a subsequent stock sale.

How many Seres Therapeutics (MCRB) shares did Brady Kelly sell and at what price?

Brady Kelly sold 64 shares of Seres Therapeutics (MCRB) Common Stock at $4.55 per share. The transaction occurred on August 17, 2026 and was reported as a sale in the open market or a private transaction.

Was Brady Kelly’s Seres Therapeutics (MCRB) stock sale under a Rule 10b5-1 plan?

Yes. The filing states the 64-share sale was effected under a Rule 10b5-1 plan adopted November 26, 2025, with the intent to cover taxes arising from the vesting of restricted stock units.

What role does Brady Kelly hold at Seres Therapeutics (MCRB)?

Brady Kelly is reported as an EVP, Chief Operating Officer of Seres Therapeutics (MCRB). The transactions disclosed relate to equity compensation (RSUs) and a subsequent sale of shares associated with that role.

How do the reported RSUs for MCRB vest over time for Brady Kelly?

The RSUs vest 25% on an initial February 15 date, with the remainder vesting and settling in 12 equal quarterly installments thereafter. The filing notes that the restricted stock units have no expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/18/2026 - 05:34 PM Accepted by SEC EDGAR 08/18/2026 - 05:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brady Kelly

(Last)

(First)

(Middle)

C/O SERES THERAPEUTICS, INC.

101 CAMBRIDGE PARK DRIVE

(Street)

CAMBRIDGE

MASSACHUSETTS

02140

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/15/2026		M		181	A	⁽¹⁾	8,743	D
Common Stock	08/17/2026		S⁽²⁾		64	D	$4.55	8,679	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	08/15/2026		M			90	⁽³⁾	⁽³⁾	Common Stock	90	$0	179	D
Restricted Stock Units	⁽¹⁾	08/15/2026		M			91	⁽⁴⁾	⁽⁴⁾	Common Stock	91	$0	548	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units.

3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.

Remarks:

EVP, Chief Operating Officer

	/s/ Thomas J. DesRosier, Attorney-in-Fact for Kelly M. Brady	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR